Now, a clinical trial presented at the American College of Cardiology Annual Scientific Sessions in March 2018 offered encouragement that the beta-blocker carvedilol
(Coreg[TM]) and the angiotensin converting enzyme inhibitor lisinopril (Prinivil[TM]) may protect certain patients taking these drugs, too.
MONDAY, March 12, 2018 (HealthDay News) -- For women with human epidermal growth factor receptor type 2 (HER2)-negative breast cancer receiving anthracycline (ANT) chemotherapy, carvedilol
does not prevent cardiotoxicity, according to a study published online March 11 in the Journal of the American College of Cardiology.
The potassium level normalized after metoprolol was discontinued, but the administration of carvedilol
subsequently induced hyperkalemia.
is a nonspecific, combined [beta]1/[beta]2/[alpha]-adrenergic blocker, which has been successfully used in the treatment of chronic heart failure .
The United States Food and Drug Administration (FDA) has granted tentative approval to Impax Laboratories Inc (NASDAQ: IPXL), a specialty pharmaceutical company, for its Abbreviated New Drug Application (ANDA) for the generic version of Coreg CR (carvedilol
phosphate) extended-release capsules, 10, 20, 40 and 80 mg, it was reported on Friday.
In terms of adverse reactions, Carvedilol
does not entirely belong to the pharmacology of its group, reason why we believe it might be useful to present its implications in this clinical case (15,16,17,18).
The drug carvedilol
can protect against the sun-induced cell damage that leads to skin cancer, the findings showed.
Besides being used as a nonselective [beta]-adrenergic blocker, carvedilol
has been studied as an antioxidant [6, 7].
An effective dose of carvedilol
has been established using healthy dogs (6-9), and some authors have reported the possible beneficial effects of beta-blocker treatment in dogs with chronic mitral valve disease (CMVD) (10,11).
Importantly, patients will still need to continue their other heart medications, such as beta-blockers (e.g., metoprolol and carvedilol
) and aldosterone blockers (e.g., spironolactone).
They also compared atenolol, bisoprolol, bucindolol, carvedilol
, metoprolol, and nebivolol with each other and found no significant difference in risk of death, sudden cardiac death, death resulting from pump failure, or tolerability.